Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
70.02
+0.61 (0.88%)
At close: Oct 24, 2025, 4:00 PM EDT
69.95
-0.07 (-0.10%)
After-hours: Oct 24, 2025, 4:27 PM EDT
Mirum Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts that cover Mirum Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $79, which forecasts a 12.82% increase in the stock price over the next year. The lowest target is $55 and the highest is $95.
Price Target: $79 (+12.82%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mirum Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 7 | 7 | 7 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 9 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $75 → $81 | Buy | Maintains | $75 → $81 | +15.68% | Oct 16, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates $95 | Strong Buy | Initiates | $95 | +35.68% | Sep 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $53 → $77 | Buy | Maintains | $53 → $77 | +9.97% | Sep 12, 2025 |
| Stifel | Stifel | Strong Buy Initiates $89 | Strong Buy | Initiates | $89 | +27.11% | Aug 11, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $77 → $89 | Buy | Maintains | $77 → $89 | +27.11% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
515.92M
from 336.89M
Increased by 53.14%
Revenue Next Year
618.23M
from 515.92M
Increased by 19.83%
EPS This Year
-0.70
from -1.85
EPS Next Year
0.01
from -0.70
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 546.0M | 685.7M | |||
| Avg | 515.9M | 618.2M | |||
| Low | 482.2M | 554.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 62.1% | 32.9% | |||
| Avg | 53.1% | 19.8% | |||
| Low | 43.1% | 7.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.30 | 0.82 | |||
| Avg | -0.70 | 0.01 | |||
| Low | -1.13 | -0.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.